Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib in VEXAS Syndrome
NCT06538181Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Feb 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pacritinib in VEXAS syndrome (VEXAS) (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Dose-limiting toxicities at 28 days and Recommended phase II dose at 28 days. Started Feb 2025; status: recruiting.
02
Drugs
pacritinib
03
Conditions
VEXAS syndrome (VEXAS)
Beyond the preview
Go deeper on NCT06538181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06538181.